Non-Alcoholic Fatty Liver Disease Trial, Recruiting (NCT05766449)

Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT05766449 Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Condition: Non-Alcoholic Fatty Liver Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05766449 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Non Alcoholic Fatty Liver Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 years or older
People who have tested positive for the hepatitis B surface antigen (a marker showing hepatitis B infection) for at least 6 months, with no other viral infections present at the start of the study
People who have been diagnosed with NAFLD (a condition where excess fat builds up in the liver, unrelated to alcohol) through imaging scans, a liver biopsy, and/or blood tests

Who may not be able to join:

People who have another chronic liver disease, such as liver disease caused by alcohol, other types of viral hepatitis, or liver damage caused by medication
People who have been diagnosed with liver cancer or any other cancer before undergoing a liver biopsy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 15863787910

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05766449

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase: Not Applicable

Status: Recruiting

Condition: Non-Alcoholic Fatty Liver Disease

Trial contact: 15863787910

More information: https://clinicaltrials.gov/study/NCT05766449

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 years or older
People who have tested positive for the hepatitis B surface antigen (a marker showing hepatitis B infection) for at least 6 months, with no other viral infections present at the start of the study
People who have been diagnosed with NAFLD (a condition where excess fat builds up in the liver, unrelated to alcohol) through imaging scans, a liver biopsy, and/or blood tests

Who may not be able to join:

People who have another chronic liver disease, such as liver disease caused by alcohol, other types of viral hepatitis, or liver damage caused by medication
People who have been diagnosed with liver cancer or any other cancer before undergoing a liver biopsy

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Registry

ClinicalTrials.gov

Start date

1 June 2022

Est. completion

1 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Risk factors for hepatic inflammation or fibrosis in chronic hepatitis B patients with non-alcoholic fatty liver disease; Risk factors of chronic hepatitis B patients with non-alcoholic fatty liver disease progressing to cirrhosis, liver cancer or liver failure; Risk factors of chronic hepatitis B patients with non-alcoholic fatty liver disease progressing to cirrhosis, liver cancer or liver failure; Risk factors of chronic hepatitis B patients with non-alcoholic fatty liver disease progressing to cirrhosis, liver cancer or liver failure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov